NASDAQ: $ILMN
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
Illumina, Inc. today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025. The company reported solid performance across its core sequencing segments, reflecting continued momentum in both clinical adoption and research applications globally.
Fourth Quarter Financial Highlights
For the fourth quarter of 2025, Illumina recorded total revenue of $1.18 billion, representing a year-over-year increase of 8%. This revenue performance exceeded the company’s expectations, driven primarily by strong uptake of high-throughput sequencing systems and increased consumables utilization in clinical genomics programs.
- GAAP Net Income: $195 million, or $1.25 per diluted share.
- Non-GAAP Net Income: $238 million, or $1.53 per diluted share, reflecting operational efficiencies achieved throughout the year.
- Gross Margin: Expanded to 72.5%, up from 69.8% in the same period last year, attributable to favorable manufacturing scaling and product mix.
Fiscal Year 2025 Performance Summary
Throughout the full fiscal year 2025, Illumina sustained revenue growth, achieving total annual revenue of $4.65 billion, an increase of 7% compared to fiscal year 2024. The company successfully integrated advancements in its Novaseq platform, which contributed significantly to research revenue.
Key achievements for the fiscal year include:
- Significant expansion of installed base for mid-throughput systems, supporting emerging biotech growth.
- Progress in regulatory submissions for several high-priority oncology testing panels.
- Strong cash flow generation, providing flexibility for strategic investments in R&D and market expansion.
Management Commentary
“We are pleased with our financial results for the fourth quarter and the full year of 2025,” stated [Fictional CEO Name], CEO of Illumina. “Our teams executed effectively against our strategic priorities, delivering growth while enhancing operational leverage. The advancements in our sequencing technology continue to lower the cost of sequencing, making powerful genomic insights accessible to a broader range of healthcare providers and researchers. We remain committed to advancing human health through genomics in 2026 and beyond.”
Outlook for Fiscal Year 2026
Looking ahead to fiscal year 2026, Illumina anticipates continued revenue growth in the low-to-mid single digits, anticipating sustained momentum from oncology and population genomics initiatives. The company projects capital expenditures to focus on scaling manufacturing capacity to meet anticipated demand for next-generation instruments.
Illumina will host a conference call later today to discuss these results in greater detail. The detailed financial tables are available in the accompanying press release materials.